Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency
- PMID: 6861853
- DOI: 10.1007/BF00610061
Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency
Abstract
The pharmacokinetics and clinical effects of cefuroxime were investigated in 5 patients with severe impairment of renal function (creatinine clearance less than or equal to 23 ml/min), suffering from an urinary tract infection. Bolus i.v. injections of cefuroxime 750 mg b.i.d. or 750 mg once daily were given to the patients depending on the degree of renal impairment. The concentration of drug in serum and urine was measured during treatment, and pharmacokinetic parameters were evaluated on the second and last days; the parameters obtained on the 2 days did not differ significantly. Drug elimination half-life increased from 4.2 h (creatinine clearance 23.0 ml/min) to 22.3 h (creatinine clearance 5.0 ml/min) with decreasing renal function. The apparent volume of distribution ranged from 11.6 to 17.9 l, and showed a substantial increase to 29.6 l in the patient with the poorest renal function. A linear correlation was found between the total and renal clearance of cefuroxime and the creatinine clearance; the extrarenal clearance was 8.24 ml/min. Concomitant treatment with furosemide did not impair renal function and no evidence of nephrotoxicity was found. The clinical efficacy of the drug was good. Symptoms of infection subsided after 3-4 days and the isolated pathogens were eradicated. No relapse or episodes of reinfection were observed in a following-up period of 3 months. The drug was well tolerated and no side effects or changes in haematological or biochemical values were seen.
Similar articles
-
Pharmacokinetic study of cefuroxime in the elderly.Br J Clin Pharmacol. 1981 Dec;12(6):801-5. doi: 10.1111/j.1365-2125.1981.tb01310.x. Br J Clin Pharmacol. 1981. PMID: 7340882 Free PMC article.
-
The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy.Eur J Clin Pharmacol. 1988;35(3):273-9. doi: 10.1007/BF00558265. Eur J Clin Pharmacol. 1988. PMID: 3053209
-
Randomized comparison of aztreonam and cefuroxime in gram-negative upper urinary tract infections.Infection. 1989 Sep-Oct;17(5):284-9. doi: 10.1007/BF01650709. Infection. 1989. PMID: 2689345 Clinical Trial.
-
Cefuroxime: mechanisms of action, antimicrobial activity, pharmacokinetics, clinical applications, adverse reactions and therapeutic indications.Pharmacotherapy. 1983 Mar-Apr;3(2 Pt 1):82-100. Pharmacotherapy. 1983. PMID: 6344037 Review.
-
Pharmacology and pharmacokinetics of cefprozil.Clin Infect Dis. 1992 Jun;14 Suppl 2:S184-8; discussion S195-6. doi: 10.1093/clinids/14.supplement_2.s184. Clin Infect Dis. 1992. PMID: 1617036 Review.
Cited by
-
Clinical pharmacokinetics of antibiotics in patients with impaired renal function.Clin Pharmacokinet. 1992 Mar;22(3):169-210. doi: 10.2165/00003088-199222030-00002. Clin Pharmacokinet. 1992. PMID: 1559311 Review.
-
Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis.Eur J Clin Pharmacol. 1985;28(2):187-91. doi: 10.1007/BF00609690. Eur J Clin Pharmacol. 1985. PMID: 3987798 Clinical Trial.
-
Guide to drug dosage in renal failure.Clin Pharmacokinet. 1988 Nov;15(5):326-54. doi: 10.2165/00003088-198815050-00005. Clin Pharmacokinet. 1988. PMID: 3060292 Review. No abstract available.
-
Physiologically based pharmacokinetic evaluation of cefuroxime in perioperative antibiotic prophylaxis.Br J Clin Pharmacol. 2019 Dec;85(12):2864-2877. doi: 10.1111/bcp.14121. Epub 2019 Dec 15. Br J Clin Pharmacol. 2019. PMID: 31487057 Free PMC article.
-
A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.Br J Clin Pharmacol. 2006 Sep;62(3):297-303. doi: 10.1111/j.1365-2125.2006.02652.x. Br J Clin Pharmacol. 2006. PMID: 16934045 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical